| 摘要 |
E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1- [(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl} ethenesulfonamide in substantially crystalline form, pharmaceutical formulations thereof, processes for preparing it, and its use inmedicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
|
